JP2024519585A5 - - Google Patents
Info
- Publication number
- JP2024519585A5 JP2024519585A5 JP2023570050A JP2023570050A JP2024519585A5 JP 2024519585 A5 JP2024519585 A5 JP 2024519585A5 JP 2023570050 A JP2023570050 A JP 2023570050A JP 2023570050 A JP2023570050 A JP 2023570050A JP 2024519585 A5 JP2024519585 A5 JP 2024519585A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- adc
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/093652 | 2021-05-13 | ||
| CN2021093652 | 2021-05-13 | ||
| PCT/CN2022/092473 WO2022237874A1 (en) | 2021-05-13 | 2022-05-12 | Antibody conjugate comprising anti-p-cadherin antibody and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519585A JP2024519585A (ja) | 2024-05-17 |
| JP2024519585A5 true JP2024519585A5 (https=) | 2025-03-12 |
Family
ID=84028119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570050A Pending JP2024519585A (ja) | 2021-05-13 | 2022-05-12 | 抗ｐ－カドヘリン抗体を含む抗体コンジュゲートおよびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240239885A1 (https=) |
| EP (1) | EP4337702A1 (https=) |
| JP (1) | JP2024519585A (https=) |
| KR (1) | KR20240007939A (https=) |
| CN (1) | CN117295770A (https=) |
| AU (1) | AU2022273147A1 (https=) |
| CA (1) | CA3218789A1 (https=) |
| CL (1) | CL2023003365A1 (https=) |
| IL (1) | IL308485A (https=) |
| WO (1) | WO2022237874A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230119179A (ko) * | 2020-12-10 | 2023-08-16 | 우시 바이올로직스 아일랜드 리미티드 | P-캐드히린에 대한 항체 및 이의 용도 |
| WO2026021443A1 (en) * | 2024-07-23 | 2026-01-29 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody-drug conjugates targeting cdh3 and preparation methods and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1560597A4 (en) * | 2002-10-29 | 2007-06-27 | Pharmacia Corp | DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF |
| CA2763671A1 (en) * | 2005-04-26 | 2006-11-02 | Pfizer Inc. | P-cadherin antibodies |
| US8703920B2 (en) * | 2008-11-10 | 2014-04-22 | The Regents Of The University Of California | Fully human antibodies against N-cadherin |
| CA2869704A1 (en) * | 2012-04-04 | 2013-10-10 | Perseus Proteomics Inc. | Drug conjugate comprising anti-cdh3 (pcadherin) antibody |
| HK1215959A1 (en) * | 2013-02-15 | 2016-09-30 | Perseus Proteomics Inc. | Anti-cdh3 humanized antibody, drug conjugate thereof, and utilization of same |
| TW201625692A (zh) * | 2014-11-14 | 2016-07-16 | 諾華公司 | 抗體藥物結合物 |
| US20190194315A1 (en) * | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
| EP3322735A4 (en) * | 2015-07-15 | 2019-03-13 | Zymeworks Inc. | ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS |
-
2022
- 2022-05-12 EP EP22806836.7A patent/EP4337702A1/en active Pending
- 2022-05-12 WO PCT/CN2022/092473 patent/WO2022237874A1/en not_active Ceased
- 2022-05-12 KR KR1020237043207A patent/KR20240007939A/ko active Pending
- 2022-05-12 AU AU2022273147A patent/AU2022273147A1/en active Pending
- 2022-05-12 US US18/560,285 patent/US20240239885A1/en active Pending
- 2022-05-12 IL IL308485A patent/IL308485A/en unknown
- 2022-05-12 CN CN202280034772.XA patent/CN117295770A/zh active Pending
- 2022-05-12 JP JP2023570050A patent/JP2024519585A/ja active Pending
- 2022-05-12 CA CA3218789A patent/CA3218789A1/en active Pending
-
2023
- 2023-11-10 CL CL2023003365A patent/CL2023003365A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008141171A (ru) | Анти-тат226 антитела и иммуноконъюгаты | |
| RU2483080C2 (ru) | Антитела и иммуноконъюгаты и их применение | |
| US9951133B2 (en) | Anti-CD33 antibodies and immunoconjugates | |
| AU2012235817B2 (en) | Antibody-drug conjugates | |
| JP2012522513A5 (https=) | ||
| CA3176248A1 (en) | Charge variant linkers | |
| JP2014139173A5 (https=) | ||
| JP2013056896A5 (https=) | ||
| JP2012522512A5 (https=) | ||
| JP2023500875A5 (https=) | ||
| FI3930847T3 (fi) | Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä | |
| JP2020526584A5 (https=) | ||
| KR20150006000A (ko) | 항-pmel17 항체 및 면역접합체 | |
| HRP20171789T1 (hr) | Konjugati humanog protutijela s lijekom protiv tkivnog faktora | |
| JP2014520088A5 (https=) | ||
| RU2009136946A (ru) | Композиции и способы диагностики и лечения опухоли | |
| CN111110862A (zh) | 抗cldn18．2抗体的药物偶联体及其制备方法和用途 | |
| JP2018520991A5 (https=) | ||
| HRP20220172T1 (hr) | Protutijela protiv cd71 koja se mogu aktivirati, te postupci njihove uporabe | |
| JP2016063817A5 (https=) | ||
| AU2016248357A1 (en) | Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof | |
| RU2020124944A (ru) | Антитела против egfr и конъюгаты антитело-лекарственное средство | |
| RU2011144119A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2018509146A (ja) | Ｆｌｔ３タンパク質に結合する抗体薬物複合体（ａｄｃ） | |
| RU2011144141A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |